6
Traitement anti-TNF alpha et suivi de la tol茅rance
18. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor 路 antagonism? Arthritis Rheum 2001;44:977-83. 19. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occuring during Anti-Tumor Necrosis Factor 路 Therapy for inflammatory Arthritides. Arthritis Rheum 2001;44:2862-69. 20. FDA meeting March 2003: Update on the safety on new drugs for rheumatoid arthritis. Part II: CHF, Infection and other safety issues. 21. Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002;16:183-200. 22. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531-4. 23. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Tnf neutralization in MS: Results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457-65.
D茅cembre 2010